A comparative study on ivermectin- doxycycline and favipiravir therapy in COVID19 patients

Abstract

We investigated the outcomes of Ivermectin-Doxycycline vs. Favipiravir therapy in mild to moderate COVID19 patients. Methods: Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for ten days in group A, and Favipiravir 1800mg for the first day, then 800mg BID for six days in group B (Control group). RT-PCR for SARS-CoV-2 infection was repeated in all symptomatic patients on the second day onward without symptoms. Repeat PCR was done every two days onward if the result found positive. Time to the negative PCR and symptomatic recovery was measured for each group. Results: All subjects in Group A reached a negative PCR, at a mean of 8.93 days, and reached symptomatic recovery, at a mean of 5.93 days, with 55.10% symptom-free by the fifth day. In group B, 96.36% reached a negative PCR at a mean of 9.33 days and were symptoms-free at 6.99 days. In group a 31.67% of patients expressed symptoms caused by medication, this was 46.43% in group B. Conclusion:The combination therapy of Ivermectin-Doxycycline showed a trend towards superiority to the combination of Favipiravir for mild to moderate COVID19 disease.